Sperm Motility Enhancers for Assisted Reproductive Technology

submit enquiry
Healthcare & Pharmaceuticals
Healthcare & Pharmaceuticals

University: University of Dundee

Sector(s): Healthcare & Pharmaceuticals

About Opportunity:

Infertility is a significant global problem affecting approximately 210 million people worldwide. The problem is increasing and the global infertility drugs market is expected to reach an estimated value of over $3.3bn by 2017, and the devices market a value of $1.4bn (www.transparencymarketresearch.com) Sperm dysfunction, and in particular poor sperm motility, has consistently been identified as the single most common cause of male infertility. Remarkably, there are no drugs a man can take, or have added to his spermatozoa, to improve or treat this condition. The only option is ART, yet sperm dysfunction impacts negatively on success rate. Identification of compounds able to increase numbers of functional sperm could significantly impact on the treatment of male infertility.

An extensive programme carried out by the Drug Discovery Unit at the University of Dundee has successfully identified several FDA-approved drugs that have a robust and effective stimulation on sperm motility. The compounds show remarkable longevity in their effect, are non-toxic and stimulate motility to a biologically and functionally significant level. Importantly, a positive response has also been demonstrated on a small target patient sample (23 patients) spanning the spectrum of mild to severe sperm dysfunction. Increasing the number of functional sperm in the vicinity of the egg will increase the probability of fertilisation and could have a marked increase on the success rates and accessibility of ART. This novel approach would allow treatment of dysfunctional sperm in vitro rather than treating the person in vivo – greatly simplifying the development package and permitting quick translation to the clinic. The addition of a stimulating compound to sperm is easily incorporated into current practice and adds no time or complexity to the procedure.

Key Benefits:

  • Identification of FDA-approved drugs that have a robust and effective stimulation on sperm motility
  • Easily incorporated into current practices and adds no time or complexity to the procedure
  • Allows treatment of dysfunctional sperm in vitro rather than treating the person in vivo


  • For treatment of dysfunctional sperm in vitro
  • The technology can be easily incorporated into current practices

IP Status:

This technology is protected by two patent applications (EP 2766016 and US 2015231149).


Please enter your name.

Please enter the name of the company you work for.

Is your company an SME?

Please select the country you are in.

Please select what part of the UK you are in.

Please select from the following options.

Please enter your email address.

To help us process your enquiry faster please enter some details about the information you are interested in.

Words remaining:

Related Opportunities

  • Telomerase Promoter - Cancer Therapies

    The University of Glasgow has developed a (Ad-hTR-NTR) which has been extensively tested on Ovarian cancer cells.

    Expires: Created:
  • SNP-based assay for analysis of MRSA

    This assay is a rapid and reproducible approach for epidemiological analysis of methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates. The assay identifies different strains on EMRSA-15, which is a major cause of hospital acquired MRSA infections in the UK and in other parts of the wo...

    Expires: Created:
  • Catanostics - Non-Invasive Early Stage Cataract Diagnosis & Severity Quantification tool

    Catanostics (Cataract Diagnostics) offers an alternative to the slit lamp currently used for cataract diagnosis before referring a patient for cataract surgery. Our non-invasive fluorescence scan offers "better diagnosis" through non-subjective analysis of data on cataract symptoms & severity lea...

    Expires: Created:
  • Transforming Pharmaceutical Crystal Forms

    The innovation provides a gas-induced method for phase-transforming organic solids, such as pharmaceutical crystals. The inventive method subjects the polymorphs of pharmaceutical agents to various pressures of gases (such as CO2, N2O, and CH4) to induce phase transform with ease.

    Expires: Created:
  • Multipurpose, Novel, Nanocomposite Coatings for Medical Devices

    Researchers at the University of Dundee have developed novel coating strategies to prevent medical device-related infections and complications.

    Expires: Created:

Alerts Signup

Sign up to our technology alerts and be the first to hear about any new technology opportunities from Scotland's universities

Register Now for University Technology.com Alerts

Search Filter

Share this page

Use the buttons below to share these technology opportunities on your favourite social networking site. You can also share them from inside the individual opportunity.